Skip to content

Effect of Circadian Light on Hospitalized Persons With Dementia and Older Adults With Cognitive Impairments.

PAX: A Randomized Single-blind Controlled Trial of the Effect of Circadian Light on Hospitalized Persons With Dementia and Older Adults With Cognitive Impairments

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05535790
Enrollment
80
Registered
2022-09-10
Start date
2022-09-01
Completion date
2024-05-01
Last updated
2022-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment, Dementia

Brief summary

Light stimulates the human visual system and the biological functions in the retina, also referred to as non-visual responses, e.g. hormone production. Exposure to the correct light composition can produce acute alertness and increase good sleep quality (1). In this study, subjects will be exposed to 24-hour LED naturalistic lighting (intervention) or traditional lighting (control) during all days of hospitalization. Subjects will be blinded to the intervention as they will not be told if they are admitted to an intervention patient room or a control patient room. The primary outcome measure is cortisol levels measured in saliva samples. Secondary outcome measures are delirium rates, length of admission, use of constant observation, mortality and adverse advent. It is estimated that 80 subjects will be included in the study.

Detailed description

During hospitalization, patient rooms are often associated with poor lighting conditions, and patients are often not exposed to outdoor activities. Many patients have difficulties sleeping during hospital admission, which affects health outcomes and potentially leads to prolonged admission and rehabilitation and a higher risk of developing delirium. However, the circadian rhythm can be modified with LED light, as this technology can reach sufficient levels to affect the human melanopic equivalent daylight illuminance (Melanopic EDI). A high melanopic EDI during the day is supportive for alertness and a good night's sleep. A good night's sleep is essential to prevent the development of delirium. LED lighting, which can give melanopic EDI, is called naturalistic light (1,2). In this study, subjects will be exposed to 24-hour LED naturalistic lighting (intervention) or traditional lighting of fluorescent tubes (control) during all days of hospitalization. Subjects will be blinded to the intervention as they will not be told if they are admitted to an intervention patient room or a control patient room. The study includes subjects who are diagnosed with dementia (mild-moderate) or older adults (+65 years) who have cognitive impairments. Subjects will be screened before inclusion using a mini-mental state examination (MMSE) (3) and clinical examination by trained specialists. To test the effect of exposure to circadian light, the study is designed as a single-centre exploratory parallel-arm randomized controlled trial. The trial will be thoroughly reported according to the CONSORT (4) statement extended guidelines The primary outcome measure is cortisol levels measured in saliva samples. The samples are collected two times each day during hospitalization. One sample is collected at \<30 minutes after the subject has woken in the morning (during the morning cortisol peak) and one sample in the evening when the highest level is expected. Secondary outcome measures are delirium rates, length of admission, need for escape prevention, mortality, use of antipsychotics and adverse advent e.g. patient related fall incidents. Delirium rates are collected by performing a confusion assessment method (CAM) (5) score two times a day. Additional measurements are collected in patient charts. To reach sufficient power, we estimate that 80 subjects will be included in the study. 40 subjects are admitted to the intervention room (with naturalistic lighting), and 40 are admitted to the control room (traditional/standard lighting conditions).

Interventions

OTHERNaturalistic LED light

Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.

OTHERStandard/traditional lighting

Standard/tradtional lighting environment with fluorescent tubes

Sponsors

Technical University of Denmark
CollaboratorOTHER
University of Copenhagen
CollaboratorOTHER
Zealand University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a recognized dementia diagnosis by the time of admission * Patients who, during admission, are found to have cognitive impairments * Patients who, during admission, are found to have delirium

Exclusion criteria

* Patients with psychiatric conditions which in and of themselves might account for the patients' cognitive impairment will be excluded * Inability to speak (aphasia) * Patients with a linguistic or cultural background other than Danish * Patients with ongoing abuse of alcohol, narcotics or sedative pharmaceutics * Patients with impaired level of consciousness due to other causes than delirium.

Design outcomes

Primary

MeasureTime frameDescription
CortisolDuring intervention periodCortisol levels measured in saliva samples

Secondary

MeasureTime frameDescription
Length of admissionDuring intervention periodLength of admission collected from patient charts
PharmaceuticsDuring intervention periodUse of pharmaceutics during hospitalization. Collected from patient charts.
DeliriumDuring intervention periodDelirium measured in CAM score
Adverse adventDuring intervention periodAdverse advent, e.g. patient related fall incidents, collected from patient charts
Constant observationDuring intervention periodNeed of constant observation from health professionals, collected from patient charts
MortalityDuring intervention periodMortality rates collected from patient charts

Contacts

Primary ContactMartin Ballegaard, MD, PhD
mbag@regionsjaelland.dk(+45) 47 32 29 09
Backup ContactLotte Olsen, MSc
losol@regionsjaelland.dk(+45) 42 60 10 21

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026